Immobilization Stress With α2-Adrenergic Stimulation Induces Regional and Transient Reduction of Cardiac Contraction Through Gi Coupling in Rats.
Stress cardiomyopathy is characterized by transient apical hypokinesia related to catecholamine overflow. Recently, excessive epinephrine administration was shown to recapitulate stress cardiomyopathy through β2-adrenoceptor (AR)-inhibitory G protein (Gi) coupling in rats. We aimed to study whether α2-AR and Gi affect cardiac contraction in rats in which emotional stress was evoked using immobilization (IMO). Echocardiography results showed that when male rats were exposed to IMO for 30 minutes and then injected with the α2-AR agonist xylazine (Xy), ejection fraction and the movement of the anterior wall (AW) were suppressed, maximally at 5 minutes post-injection, whereas posterior wall (PW) movement was preserved. At the same time points, the phosphorylation of Ser282 in myosin-binding protein-C (MyBP-C-Ser282) was higher in the PW than in the AW. Pretreatment with the Gi inhibitor pertussis toxin (PTX) reversed the low contractility and MyBP-C-Ser282 phosphorylation in the AW, but induced lethal heart failure in 3 out of 11 rats. Moreover, at 5 minutes after Xy injection following 30 minutes of IMO, serum epinephrine levels were increased. Thus, in rats exposed to psychological stress, α2-AR stimulation triggered transient hypo-contractility and MyBP-C-Ser282 hypo-phosphorylation in the AW, in association with an epinephrine surge. PTX treatment reversed the AW hypo-contractility and MyBP-C hypo-phosphorylation, but induced acute heart failure. These findings suggest α2AR/Gi-dependent signaling attenuates MyBP-C phosphorylation and contractility in the AW through an epinephrine surge in rats subjected to IMO and α2-AR stimulation. This model can recapitulate stress cardiomyopathy and thereby deepen our understanding of regional cardiac hypo-contractility and prosurvival mechanisms.
Department of Forensic Medicine, Graduate School of Medicine, The University of Tokyo.
Ryohei
R
Kuroda
Kaori
K
Shintani-Ishida
Kana
K
Unuma
Ken-ichi
K
Yoshida
D058647:Adrenergic alpha-2 Receptor Agonists / Q000494:pharmacology; D000818:Animals; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2 / Q000378:metabolism; D002352:Carrier Proteins / Q000378:metabolism; D004195:Disease Models, Animal; D004452:Echocardiography; D004837:Epinephrine / Q000378:metabolism*; D019206:GTP-Binding Protein alpha Subunits, Gi-Go / Q000378:metabolism*; D006333:Heart Failure / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D008297:Male; D009200:Myocardial Contraction / Q000502:physiology*; D037342:Pertussis Toxin / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D051381:Rats; D018343:Receptors, Adrenergic, beta-2 / Q000378:metabolism*; D012149:Restraint, Physical / Q000379:methods; D013315:Stress, Psychological / Q000150:complications / Q000378:metabolism; D054549:Takotsubo Cardiomyopathy / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D013997:Time Factors; D014991:Xylazine / Q000494:pharmacology; D000099163:Myosin Binding Protein C
D058647:Adrenergic alpha-2 Receptor Agonists; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2; D002352:Carrier Proteins; D004837:Epinephrine; D019206:GTP-Binding Protein alpha Subunits, Gi-Go; D037342:Pertussis Toxin; D018343:Receptors, Adrenergic, beta-2; D014991:Xylazine; D000099163:Myosin Binding Protein C